on Evotec AG (NASDAQ:EVTCY)
Evotec Announces Transition of Chief Scientific Officer
Evotec SE has announced a leadership transition as Chief Scientific Officer Dr. Cord Dohrmann is set to step down on September 30, 2026. Dr. Dohrmann, who has significantly contributed to Evotec’s scientific achievements over the last 16 years, will leave by mutual consent. The company is currently searching for his successor.
Evotec's CEO, Dr. Christian Wojczewski, praised Dr. Dohrmann for his role in enhancing the firm's scientific capabilities, particularly in areas like iPSC-based technologies. This scientific foundation is viewed as critical for Evotec’s ongoing growth.
Dr. Dohrmann expressed gratitude for the collaborations during his tenure and looks forward to witnessing the continued scientific advancements at Evotec.
This change marks a new chapter for Evotec, promising continued innovation in drug discovery and development.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Evotec AG news